Ek K.

EK K. has extensive experience in precision medicine and diagnostics, currently serving as the US Bemarituzumab Diagnostic Launch Lead at Amgen since 2020, where responsibilities include leading biomarker and diagnostic commercialization strategies for oncology. Prior roles include Global Director of Precision Medicine Strategy at AstraZeneca, leading efforts in immuno-oncology, and Head of Product Development for Companion Diagnostics at Personal Genome Diagnostics, focusing on liquid biopsy products. Earlier career milestones at Roche involved positions as Development Leader and Sr. Scientist. EK K. holds a Ph.D. in Molecular Biophysics and Biochemistry and has been educated at prestigious institutions, including the University of Southern California and Stanford University.